pubmed.ncbi.nlm.nih.gov

Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide - PubMed

️Invalid Date

Review

Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide

Jan Endrikat et al. Contraception. 2011 Dec.

Abstract

Background: The objective of this analysis was to provide a comprehensive review of ovulation inhibition data of progestins currently available worldwide. This analysis may serve as a reference tool for research on new progestin molecules.

Study design: We used literature search engines to detect data of progestin monotherapies on ovulation inhibition in humans. Only treatments with stable dosing during a cycle were accepted. In a second step, we tried to estimate the 99% ovulation inhibiting doses and their fiducial confidence limits using the probit dose-response model. Finally, we analyzed the progestin doses of combined oral contraceptives currently on the market.

Results: We found original data on 29 marketed and nonmarketed progestins in a total of 60 publications, published between 1956 and May 2010. Details on methods used for determining ovulation, number of doses and daily dose of each tested progestin, number of subjects, cycles and ovulations are summarized in a table. We designed one example of a dose-response curve using the statistical model. For most progestins, literature data were insufficient for this purpose. A total of 13 progestins are components of oral contraceptives currently on the market worldwide, five of them in combination with 20 mcg ethinyl estradiol (EE).

Conclusion: This review provides a comprehensive overview of all progestins ever tested for their ovulation inhibition potency and a summary of all preparations currently on the world market, including their regimens and their combinations with EE.

PubMed Disclaimer

Cited by

Hormone-based models for comparing menstrual cycle and hormonal contraceptive effects on human resting-state functional connectivity.
Casto KV, Jordan T, Petersen N. Casto KV, et al. Front Neuroendocrinol. 2022 Oct;67:101036. doi: 10.1016/j.yfrne.2022.101036. Epub 2022 Sep 17. Front Neuroendocrinol. 2022. PMID: 36126748 Free PMC article.
Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?
Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Nappi RE, et al. J Headache Pain. 2013 Aug 1;14(1):66. doi: 10.1186/1129-2377-14-66. J Headache Pain. 2013. PMID: 24456509 Free PMC article. Review.
The benefits of estetrol addition to drospirenone for contraception.
Foidart JM, Gemzell-Danielsson K, Kubba A, Douxfils J, Creinin MD, Gaspard U. Foidart JM, et al. AJOG Glob Rep. 2023 Sep 18;3(4):100266. doi: 10.1016/j.xagr.2023.100266. eCollection 2023 Nov. AJOG Glob Rep. 2023. PMID: 37854030 Free PMC article.
The effectiveness of quick starting oral contraception containing nomegestrol acetate and 17-β estradiol on ovulation inhibition: A randomized controlled trial.
Jirakittidul P, Angsuwathana S, Rattanachaiyanont M, Thiampong T, Neungton C, Chotrungrote B. Jirakittidul P, et al. Sci Rep. 2020 May 29;10(1):8782. doi: 10.1038/s41598-020-65642-5. Sci Rep. 2020. PMID: 32472012 Free PMC article. Clinical Trial.
Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.
Cockrum RH, Soo J, Ham SA, Cohen KS, Snow SG. Cockrum RH, et al. Obstet Gynecol. 2022 Sep 1;140(3):477-487. doi: 10.1097/AOG.0000000000004896. Epub 2022 Aug 3. Obstet Gynecol. 2022. PMID: 35926206 Free PMC article.

Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide - PubMed